151 related articles for article (PubMed ID: 30591425)
1. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.
Stewart JR; Desai N; Rizvi S; Zhu H; Goff HW
Eur J Dermatol; 2018 Dec; 28(6):764-774. PubMed ID: 30591425
[TBL] [Abstract][Full Text] [Related]
2. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
5. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Talpur R; Thompson A; Gangar P; Duvic M
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
[TBL] [Abstract][Full Text] [Related]
6. Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.
Di Raimondo C; Vaccarini S; Nunzi A; Rapisarda V; Zizzari A; Meconi F; Monopoli A; Narducci MG; Scala E; Bianchi L; Tesei C; Cantonetti M
Dermatol Ther; 2022 Jun; 35(6):e15482. PubMed ID: 35373414
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
[TBL] [Abstract][Full Text] [Related]
8. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
Lundin J; Hagberg H; Repp R; Cavallin-Ståhl E; Fredén S; Juliusson G; Rosenblad E; Tjønnfjord G; Wiklund T; Osterborg A
Blood; 2003 Jun; 101(11):4267-72. PubMed ID: 12543862
[TBL] [Abstract][Full Text] [Related]
10. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
[TBL] [Abstract][Full Text] [Related]
11. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
Novelli S; García-Muret P; Sierra J; Briones J
J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
[TBL] [Abstract][Full Text] [Related]
14. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Duvic M
Hematology Am Soc Hematol Educ Program; 2015; 2015():529-44. PubMed ID: 26637769
[No Abstract] [Full Text] [Related]
15. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab.
Weder P; Anliker M; Itin P; Bargetzi M
Dermatology; 2004; 208(3):281-3. PubMed ID: 15118391
[TBL] [Abstract][Full Text] [Related]
16. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
[TBL] [Abstract][Full Text] [Related]
19. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate and Pralatrexate.
Wood GS; Wu J
Dermatol Clin; 2015 Oct; 33(4):747-55. PubMed ID: 26433846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]